Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRND known ✓ | Q07001 | 5/20 | 0.48 |
| ▸ | CHRNA1 known ✓ | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG known ✓ | P07510 | 1/20 | 0.48 |
| ▸ | CHRNB1 known ✓ | P11230 | 1/20 | 0.48 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL906366 | 1.00 | GRIA1 (0.49) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL620470 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL28031750 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL620471 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL8975007 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL23778217 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL28379862 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL38651117 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL28663068 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL7142929 | 0.99 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 850 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4487869-A2 | RNA ENCODING A TUMOR ANTIGEN | CureVac SE (DE) | 2025-01-08 | — | — | EP | claimed |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | CureVac SE (DE) | 2024-03-21 | — | — | US | claimed |
| US-20210401971-A1 | MERS CORONAVIRUS VACCINE | CUREVAC AG (DE) | 2021-12-30 | — | — | US | claimed |
| EP-3777881-A1 | RNA ENCODING A TUMOR ANTIGEN | CureVac AG (DE) | 2021-02-17 | — | — | EP | claimed |
| US-20210030864-A1 | BUNYAVIRALES VACCINE | CureVac SE (DE) | 2021-02-04 | — | — | US | claimed |
| EP-3673069-A1 | BUNYAVIRALES VACCINE | CureVac AG (DE) | 2020-07-01 | — | — | EP | claimed |
| US-20200085942-A1 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-03-19 | — | — | US | claimed |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-01-16 | — | — | US | claimed |
| US-20190351048-A1 | MERS CORONAVIRUS VACCINE | CureVac SE (DE) | 2019-11-21 | — | — | US | claimed |
| US-20190351044-A1 | LASSA VIRUS VACCINE | CureVac SE (DE) | 2019-11-21 | — | — | US | claimed |
| EP-2083851-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | Curevac GmbH (DE) | 2009-08-05 | — | — | EP | claimed |
| WO-2009046739-A1 | COMPOSITION FOR TREATING PROSTATE CANCER (PCA) | CUREVAC GMBH (DE) | 2009-04-16 | — | — | WO | claimed |
| EP-2046954-A2 | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | Curevac GmbH (DE) | 2009-04-15 | — | — | EP | claimed |
| WO-2008052770-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2008-05-08 | — | — | WO | claimed |
| WO-2008014979-A2 | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | CUREVAC GMBH (DE) | 2008-02-07 | — | — | WO | claimed |
| EP-1829552-A2 | Chlamydia PMP proteins, gene sequences and uses thereof | Emergent Product Development Gaithersburg Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| EP-1487477-A4 | METHODS OF USING FLT3-LIGAND IN IMMUNIZATION PROTOCOLS | IMMUNEX CORP (US) | 2006-07-19 | — | — | EP | claimed |
| EP-1487477-A2 | METHODS OF USING FLT3-LIGAND IN IMMUNIZATION PROTOCOLS | Immunex Corporation (US) | 2004-12-22 | — | — | EP | claimed |
| US-20040022760-A1 | Methods of using Flt3-ligand in immunization protocols | IMMUNEX CORPORATION | 2004-02-05 | — | — | US | claimed |
| WO-2003083083-A2 | METHODS OF USING FLT3-LIGAND IN IMMUNIZATION PROTOCOLS | IMMUNEX CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190351044-A1 | LASSA VIRUS VACCINE | LASP1, LAS1L, LTA | CHRND 4759/4885CHRNA1 3788/4885CHRNG 4431/4885 |
| US-20210030864-A1 | BUNYAVIRALES VACCINE | RNGTT, CHIA, TRMT1 | CHRND 3401/4885CHRNA1 2925/4885CHRNG 3106/4885 |
| US-20190351048-A1 | MERS CORONAVIRUS VACCINE | SARS1, RNMT, ACE2 | CHRND 1853/4885CHRNA1 1298/4885CHRNG 1295/4885 |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | SARS1, RNMT, ACE2 | CHRND 1853/4885CHRNA1 1298/4885CHRNG 1295/4885 |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | TLR9, TLR3, TLR5 | CHRND 1699/4885CHRNA1 307/4885CHRNG 281/4885 |
| US-20210401971-A1 | MERS CORONAVIRUS VACCINE | SARS1, RNMT, ACE2 | CHRND 1853/4885CHRNA1 1298/4885CHRNG 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.